Related Experiment Video

Updated: Jun 13, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors

Anupa K Patel1, Vivian Fonseca

  • 1Department of Endocrinology & Metabolism, Scott & White Hospital/Texas A&M Health Sciences Center, Temple, 76508, USA. akpatel@swmail.sw.org

Current Diabetes Reports
|April 29, 2010
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibition shows promise for managing hyperglycemia in type 2 diabetes. Clinical trials indicate favorable glycemic control and potential reduction in diabetes complications with SGLT2 inhibitors.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Background:

  • Hyperglycemia is a key factor in type 2 diabetes complications.
  • Existing oral therapies have limitations in managing hyperglycemia.
  • Kidney-based glucose reabsorption presents a therapeutic target.

Purpose of the Study:

  • To review clinical trials on sodium-glucose cotransporter-2 (SGLT2) inhibition.
  • To assess the efficacy of SGLT2 inhibitors in managing hyperglycemia.
  • To evaluate the potential of SGLT2 inhibitors in reducing diabetes complications.

Main Methods:

  • Review of clinical trial data on SGLT2 inhibitors.
  • Analysis of glycemic and metabolic parameters in patients.
  • Assessment of SGLT2 inhibition as monotherapy and adjunct therapy.

Main Results:

  • SGLT2 inhibition demonstrates favorable responses in glycemic control.
  • Metabolic parameters show improvement with SGLT2 inhibition.
  • Positive effects observed with SGLT2 inhibitors as monotherapy and with other antidiabetic agents.

Conclusions:

  • SGLT2 inhibition is a promising approach for hyperglycemia management in type 2 diabetes.
  • Further research is needed to confirm long-term efficacy and safety of SGLT2 inhibitors.
  • SGLT2 inhibitors may offer a novel strategy to mitigate diabetes-related complications.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...